EyePoint Pharma slips after announcing $150 mln stock offering

EyePoint

14/10/2025 22:07

** Shares of EyePoint Pharmaceuticals EYPT.O down 2.1% in extended trading at $12.89 as it looks to raise equity

** Watertown, Massachusetts-based EYPT commences $150 mln stock offering

** Co plans to use net offering proceeds to advance the development of its drug, Duravyu, for wet age related macular degeneration (wet AMD) and diabetic macular edema (DME), and support its earlier stage pipeline development initiatives

** It also announces Phase 3 program initiation for Duravyu in DME, an eye condition that causes blurry vision in people with diabetes, with first patient dosing anticipated in Q1 2026

** JP Morgan, Jefferies, Citigroup, and Guggenheim Secs are joint bookrunners for stock offering

** EYPT has ~69 mln shares outstanding

** Shares on Tues ended down 1.3% at $13.16, trimming YTD gain to about 77%

** All 13 analysts covering the stock are bullish, including 4 "strong buy" ratings, and their median PT is $29.50, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))